U.S. Markets open in 2 hrs 57 mins

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.51+0.03 (+0.32%)
At close: 4:00PM EDT

9.27 -0.24 (-2.52%)
Pre-Market: 4:32AM EDT

Affimed N.V.

Technologiepark
Im Neuenheimer Feld 582
Heidelberg 69120
Germany
49 6221 6743 60
http://www.affimed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees153

Key Executives

NameTitlePayExercisedYear Born
Dr. Adi HoessCEO, MD & Member of Management Board754.87kN/A1961
Dr. Wolfgang FischerMD, COO & Member of Management Board605.09kN/A1964
Prof. Melvyn LittleFounder & ConsultantN/AN/AN/A
Mr. Angus W. SmithChief Financial OfficerN/AN/A1982
Dr. Arndt J. G. SchotteliusChief Scientific OfficerN/AN/A1966
Mr. Michael WolfHead of Fin. & Admin.N/AN/A1967
Mr. Alexander FudukidisHead of Investor RelationsN/AN/AN/A
Dr. Uwe ReuschHead of Cell CultureN/AN/AN/A
Dr. Stefan KnackmussHead of Antibody ScreeningN/AN/AN/A
Dr. Sergey KipriyanovHead of R&DN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Corporate Governance

Affimed N.V.’s ISS Governance QualityScore as of April 1, 2021 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.